Talecris' Gamunex approved for new use
Published: Sat, Sep. 13, 2008 12:30AM
Modified Sat, Sep. 13, 2008 01:41AM
E-Mail
Print
tool name
closeCLAYTON -- Gamunex, a medicine that Research Triangle Park-based Talecris Biotherapeutics makes at its Clayton plant, received regulatory approval Friday as the first treatment for chronic inflammatory demyelinating polyneuropathy, or CIDP.
That will make it easier and more affordable for CIDP patients to get a prescription.
The Food and Drug Administration approved Gamunex to treat primary immune deficiency in 2003. It is also one of three medicines physicians used to treat CIDP, a rare and disabling disease that damages the nerves' protective sheathing. But lacking regulatory approval, all three were often medicines of last resort, and some patients couldn't afford to pay as much as $40,000 for a year's worth of treatment.
More Business
All rights reserved. This copyrighted material may not be published, broadcast or redistributed in any manner.
Get it all with convenient home delivery of The News & Observer.
The News & Observer is pleased to be able to offer its users the opportunity to make comments and hold conversations online. However, the interactive nature of the internet makes it impracticable for our staff to monitor each and every posting.
Since The News & Observer does not control user submitted statements, we cannot promise that readers will not occasionally find offensive or inaccurate comments posted on our website. In addition, we remind anyone interested in making an online comment that responsibility for statements posted lies with the person submitting the comment, not The News and Observer.
If you find a comment offensive, clicking on the exclamation icon will flag the comment for review by the administrators, we are counting on the good judgment of all our readers to help us.
